“Computational Analysis of FDA-Approved Drugs for Potential Repurposing in Alzheimer’s Disease: Targeting mTOR and NGFR Pathways” (2026) Science Essence Journal, 42(1), pp. 50–70. doi:10.69523/sej.2026.42.17130.